DMYD B — Diamyd Medical AB Share News
0.000.00%
Last trade - 00:00- SEK156.53m
- -SEK93.80m
- SEK0.48m
Brief: Diamyd's Retogatein Delays Insulin Requiring Type-1 Diabetes For More Than 5 Years
Brief: Diamyd Medical Closes DIAGNODE-3 Trial
Brief: Mathias Skalmstad New CFO At Diamyd Medical
Brief: Diamyd Medical Q3 Net Sales SEK 0.1 Mln
Brief: Diamyd Medical Provides Update On Strategic Review
Brief: Diamyd Medical Begins Search For New CFO
Brief: Diamyd Gets Notice Of Allowance For Key Patent
Brief: Diamyd Medical CFO Decides To Leave His Position
Brief: Diamyd Medical Gets GMP Certification, Manufacturing Authorization
Brief: Diamyd Medical Updates On Strategic Review, Financial Position
Brief: Diamyd Medical Received Positive Feedback From Swedish Medical Products Agency
Brief: Diamyd Medical Appoints Chairman, CEO
Brief: Diamyd Medical Discontinues Diagnode-3 Following Evaluation Confirming Futility Initiates Strategic Review
Brief: Diamyd Medical AB Announces Unexpected Interim Results In Phase 3 Diagnode-3 Trial
Brief: Diamyd Medical AB - Completes Interim Efficacy Analysis In Phase 3 Diagnode-3 Trial
Brief: Diamyd Medical Announces $125 Mln Equity Financing Agreements with U.S. sector specialist investors
Brief: Diamyd Medical Receives Notice Of Grant In Japan
Brief: Diamyd Medical Gets Notice Of Allowance For Retogatein U.S. Patent
Brief: Diamyd Medical Q1 Net Loss Widens To SEK 48.8 Mln